Loading
Old version — revision 2
This is a fixed snapshot of Rapamycin, saved by Import. It is not edited and it is not updated; the article may have changed since. 1 later revision has been saved.
Edit summary: Re-import of content/rapamycin.md — the file changed after the initial import. Not an edit.
Read the current versionWhat changed sinceWhat this revision changedAll 3 revisions
A macrolide immunosuppressant that inhibits the mTOR growth pathway and extends lifespan across several laboratory species, with no confirmed effect on human aging.
Rapamycin is a bacterial macrolide, marketed as sirolimus, that inhibits the mechanistic target of rapamycin (mTOR), the kinase complex through which cells decide whether conditions favour growth or conservation. It is one of the few compounds shown to extend lifespan in yeast, nematodes, flies and mice, and it is the most reproducible positive result in the US National Institute on Aging's Interventions Testing Program. Whether it does anything for human aging is unknown. The human trials run so far have tested immune and functional surrogates in small populations, and the one large randomized trial of a related compound failed its primary endpoint.
mTOR sits at the centre of nutrient sensing. As part of complex 1 (mTORC1) it integrates amino-acid availability, growth-factor signalling and cellular energy state. When those inputs are favourable, it drives protein synthesis through S6 kinase and 4E-BP1, promotes ribosome biogenesis and suppresses Autophagy. Rapamycin does not bind mTOR directly. It first binds the small protein FKBP12, and the resulting complex docks onto mTORC1 and restricts its activity allosterically.
Inhibiting mTORC1 therefore shifts a cell from building to recycling. Autophagic flux rises, damaged organelles and aggregated proteins are degraded, and the burden on the protein quality-control system falls. Caloric restriction engages the same axis through diet, and that overlap is the main reason mTOR inhibition is treated as a pharmacological approximation of dietary restriction and not as an independent mechanism.
The complication is mTORC2. Acute rapamycin spares it, but chronic exposure disrupts its assembly in some tissues, and mTORC2 inhibition is associated with insulin resistance and glucose intolerance.1 Much of the current interest in intermittent dosing, and in mTORC1-selective inhibitors built to leave complex 2 untouched, follows from this one pharmacological fact.
Why mTOR keeps appearingNearly every intervention that reliably extends lifespan in a model organism (dietary restriction, reduced growth-hormone signalling, several genetic mutants including the long-lived daf-2 nematodes) converges on reduced mTORC1 output and increased autophagy. Rapamycin is the most direct available way to hit that node with a drug.
The mouse result is unusually robust. In the ITP, rapamycin extended median and maximal lifespan even when treatment began at an age equivalent to human late middle age,2 and the effect has been replicated across ITP cohorts and sites, a standard the field rarely meets. Higher doses produce larger effects, and females generally respond more strongly, a sex difference that has never been fully explained.3
Lifespan is not the same as Healthspan. Treated mice show delayed decline in several tissues, including reduced accumulation of senescent cells and better maintenance of immune and cognitive function, but other age-related pathologies proceed unchanged. Rapamycin does not produce the uniform rejuvenation across the Hallmarks of aging that popular accounts imply. The most informative test underway outside the laboratory is in companion dogs, where the Dog Aging Project's randomized trial tests cardiac and cognitive outcomes over years. An earlier ten-week pilot reported improved echocardiographic measures, and the programme's funding was disrupted in 2024. A separate commercial effort, Loyal, is pursuing canine lifespan drugs with other mechanisms through the veterinary regulator. In common marmosets, daily dosing has been reported as well tolerated, with no established lifespan effect.
No trial has tested whether rapamycin changes how long people live or how long they stay healthy. The human evidence that exists falls into three groups.
The first is decades of transplant experience, which establishes the safety profile at immunosuppressive doses: stomatitis and mouth ulcers, raised blood lipids, impaired glucose handling, delayed wound healing, oedema and increased infection risk. Geroscience does not propose to use these doses.
The second is immune-function work at low or intermittent doses. Rapalog treatment improved influenza vaccine responses in older adults4 and, in a follow-up combination study, was associated with fewer reported respiratory infections. Those results gave the field its most cited paradox: a drug classed as an immunosuppressant appeared to improve some aspects of immune function in the old, plausibly by reducing the accumulation of exhausted and senescent lymphocytes that also drives Inflammaging. The later phase 3 trial of RTB101 failed, the strongest single piece of negative human evidence about the strategy.
The third is the PEARL trial, a decentralized, placebo-controlled study of weekly rapamycin in healthy adults over 48 weeks. It reported no serious adverse events and a small number of favourable secondary measures, with most prespecified outcomes unchanged. It was neither designed nor powered to detect a change in aging.
Off-label use runs ahead of evidenceA minority of physicians prescribe rapamycin off-label for longevity, and a self-selected community of users takes it. Surveys of that population report a tolerable side-effect profile at intermittent doses, but self-reported outcomes from people who chose the drug cannot establish benefit, and no dose, schedule or monitoring standard has been validated for healthy adults.
The question of dose and schedule is unresolved. Animal lifespan data come from continuous exposure at concentrations that would be immunosuppressive in humans, while the human longevity community uses weekly pulses chosen largely by inference from mTORC2 pharmacology. Nobody knows whether the pulsed schedule keeps the effect that the continuous schedule produced in mice.
The endpoint question is harder still. No regulator accepts a measure of biological aging as a surrogate, so a trial would have to be powered on disease events over years. A shift in an Epigenetic clocks reading or in a composite age estimate is not evidence of clinical benefit. Rapamycin is also generic, so no company has a commercial reason to fund such a trial. The same structural problem has stalled the TAME trial, which Nir Barzilai has spent more than a decade trying to finance, and it is why the The longevity dividend remains an argument for research and not a description of an available drug.
Two lines of work could break the impasse. Bi-steric and other mTORC1-selective inhibitors, designed to leave complex 2 alone, would remove the metabolic penalty that limits chronic dosing and would test whether the metabolic side effects can be separated from the geroprotective effect. Narrow indications with measurable endpoints, among them vaccine response, periodontal disease, ovarian reserve and age-related cardiac decline, offer trials short enough to run and specific enough to interpret.
Until one of those produces a positive controlled result, rapamycin sits in an awkward position. It has the best animal evidence in geroscience and a plausible mechanism that converges with Senolytics and dietary restriction on shared damage pathways. It has nothing in humans that would justify recommending it to a healthy person over interventions with actual outcome data, starting with exercise.
paperLamming, D.W. et al. "Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity." Science, 2012. ↩
paperHarrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature, 2009.↩The Interventions Testing Program ran this at three sites in genetically heterogeneous mice; dosing was continuous in food, not the intermittent schedule people take off-label.
paperMiller, R.A. et al. "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction." Aging Cell, 2014. ↩
paperMannick, J.B. et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine, 2014.↩The drug tested was the rapalog everolimus rather than rapamycin, and the endpoint was antibody titre after influenza vaccination rather than any infection outcome.